Axol
Axol supplies high-quality human cells – especially live human neurons – created by stem cell technology, to many of the world’s biggest and best-known pharma companies and research institutions, to be used for medical research, disease modelling and drug development.
Axol generates stem cells from blood and tissue cells, extracted from healthy and diseased patients. These cells are able to self-renew and may be used to become any tissue in the human body. Importantly, Axol’s unique and innovative approach to this process means that each cell line it produces for customers will be identical to the last production batch, ensuring the quality and consistency required for research and drug development projects. Once a new cell line is developed from a healthy or diseased individual, it is added to Axol’s suite of ‘off the shelf’ products which may be purchased on their website.
The combination of these properties means the stem cells supplied by Axol are hugely important for research into treatments for many serious illnesses and diseases, including Alzheimer’s and Huntington’s. Their impressive client list includes global pharmaceutical and biotech companies as well as leading academic institutes, such as Harvard University, King’s College London and Oxford and Cambridge Universities.
Amadeus contact
In the media
14th February 2019
Investing for a better world
Take Axol Bioscience , for instance. Countries across the developed world are facing demographic timebombs – rapidly ageing populations that will mean a much higher prevalence of age-associated diseases such as Alzheimer’s.
30th January 2019
Optogenetic control of iPS cell?derived neurons in 2D and 3D culture systems using channelrhodopsin?2 expression driven by the synapsin?1 and calcium?calmodulin kinase II promoters
In contrast, human induced pluripotent stem cell?derived neural progenitor cells (hiPSC?NPC; AXOL13 and AXOL15 cell lines), purchased from Axol Bioscience, Cambridge, United Kingdom. HiPSC?NPC cells (50,000 cells/cm 2 ) were plated onto
30th January 2019
Optogenetic control of iPS cell?derived neurons in 2D and 3D culture systems using channelrhodopsin?2 expression driven by the synapsin?1 and calcium?calmodulin kinase II promoters
In contrast, human induced pluripotent stem cell?derived neural progenitor cells (hiPSC?NPC; AXOL13 and AXOL15 cell lines), purchased from Axol Bioscience, Cambridge, United Kingdom. HiPSC?NPC cells (50,000 cells/cm 2 ) were plated onto